Evidence map›Paper›PMID 36714122›Full record

ArticleFrontiers in medicine2022

Improving care for patients with

Lucy Hocking, Mark Wilcox, Nicola Petrosillo, Paul Griffin, Theodore Steiner, Gail Attara, Joel Doré, Mark Cabling, Stephanie Stockwell, Robert J Romanelli and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Lucy HockingRAND Europe, Cambridge, United Kingdom.
Mark WilcoxSchool of Medicine, University of Leeds, Leeds, United Kingdom.
Nicola PetrosilloPoliclinico Universitario, Bio-Medico Campus University Hospital, Rome, Italy.
Paul GriffinMater Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Theodore SteinerDivision of Infectious Diseases, The University of British Columbia, Vancouver, BC, Canada.
Gail AttaraCanadian Society of Intestinal Research, Vancouver, BC, Canada.
Joel DoréINRAE, MetaGenoPolis, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, France.
Mark CablingRAND Europe, Cambridge, United Kingdom.
Stephanie StockwellRAND Europe, Cambridge, United Kingdom.
Robert J RomanelliRAND Europe, Cambridge, United Kingdom.
Sonja MarjanovicRAND Europe, Cambridge, United Kingdom.
RAND Europe · GBAgroParisTech · FRCampus Bio Medico University Hospital · ITCanadian Society of Intestinal Research · CALeeds Teaching Hospitals NHS Trust · GBThe University of Queensland · AUUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Arriving at a Methods: We draw on narrative review, consultations with clinical experts and patient representatives, and a survey of 95 clinical and microbiology experts from the UK, France, Italy, Australia and Canada, adding novel multi-method evidence to the knowledge base. Results and discussion: We examine the patient pathway and variations in clinical practice and identify, synthesize insights on and discuss associated challenges. Examples of key challenges include the need to conduct multiple tests for a conclusive diagnosis, treatment side-effects, the cost of some antibiotics and barriers to access of fecal microbiota transplantation, difficulties in distinguishing recurrence from new infection, workforce capacity constraints to effective monitoring of patients on treatment and of recurrence, and ascertaining whether a patient has been cured. We also identify key opportunities and priorities for improving patient care that target both clinical practice and the wider healthcare system. While there is some variety across surveyed countries' healthcare systems, there is also strong agreement on some priorities. Key improvement actions seen as priorities by at least half of survey respondents in at least three of the five surveyed countries include: developing innovative products for both preventing (Canada, Australia, UK, Italy, and France) and treating (Canada, Australia, and Italy) recurrences; facilitating more multidisciplinary patient care (UK, Australia, and France); updating diagnosis and treatment guidelines (Australia, Canada, and UK); and educating and supporting professionals in primary care (Italy, UK, Canada, and Australia) and those in secondary care who are not CDI experts (Italy, Australia, and France) on identifying symptoms and managing patients. Finally, we discuss key evidence gaps for a future research agenda.

Indexed as

C. difficile infectionClostridioides difficileClostridium difficilehealthcare improvementhealthcare systemspatient pathway

Identifiers

PMID36714122
PMCPMC9877614
OpenAlexW4315640724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.